XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue | 6 Months Ended
--- | ---
Jun. 30, 2025
Revenue from Contract with Customer [Abstract] |
Revenue | Revenue The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Net product revenue | $ | 14,726.0 |  |  | $ | 10,354.9 |  |  | $ | 26,327.2 |  |  | $ | 18,151.4 |
Collaboration and other revenue | 831.7 |  |  | 947.9 |  |  | 1,959.0 |  |  | 1,919.4 |
Revenue | $ | 15,557.7 |  |  | $ | 11,302.8 |  |  | $ | 28,286.2 |  |  | $ | 20,070.8 |
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront, and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue resulting from our collaboration with Boehringer Ingelheim discussed in Note 4, as well as the sale of product rights. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers. Adjustments to Revenue Adjustments to revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were 1 percent and less than 1 percent of U.S. revenue during the three and six months ended June 30, 2025, respectively, and 4 percent and 3 percent of U.S. revenue during the three and six months ended 2024, respectively. Disaggregation of Revenue The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended June 30, 2025 and 2024:
| Three Months Ended June 30,
| 2025 |  | 2024
| U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total
Cardiometabolic Health: |  |  |  |  |  |  |
Mounjaro | $ | 3,301.8 |  | $ | 1,897.1 |  | $ | 5,198.9 |  |  | $ | 2,413.7 |  | $ | 677.2 |  | $ | 3,090.8 |
Zepbound | 3,379.9 |  | 1.5 |  | 3,381.4 |  |  | 1,243.2 |  | — |  | 1,243.2 |
Trulicity | 743.8 |  | 348.4 |  | 1,092.2 |  |  | 876.7 |  | 368.9 |  | 1,245.6 |
Jardiance(1) | 382.2 |  | 307.8 |  | 690.0 |  |  | 428.9 |  | 340.7 |  | 769.6 |
Other cardiometabolic health | 555.7 |  | 424.7 |  | 980.4 |  |  | 753.6 |  | 411.7 |  | 1,165.4 |
Total cardiometabolic health | 8,363.4 |  | 2,979.5 |  | 11,342.9 |  |  | 5,716.1 |  | 1,798.5 |  | 7,514.6 |
Oncology: |  |  |  |  |  |  |
Verzenio | 929.0 |  | 560.3 |  | 1,489.3 |  |  | 861.4 |  | 470.5 |  | 1,331.9 |
Other oncology | 490.3 |  | 434.0 |  | 924.3 |  |  | 413.8 |  | 413.0 |  | 826.8 |
Total oncology | 1,419.3 |  | 994.3 |  | 2,413.6 |  |  | 1,275.2 |  | 883.5 |  | 2,158.7 |
Immunology: |  |  |  |  |  |  |
Taltz | 548.8 |  | 298.8 |  | 847.6 |  |  | 539.4 |  | 285.3 |  | 824.7 |
Other immunology | 152.1 |  | 255.8 |  | 408.0 |  |  | 60.4 |  | 197.3 |  | 257.7 |
Total immunology | 700.9 |  | 554.6 |  | 1,255.6 |  |  | 599.8 |  | 482.6 |  | 1,082.4 |
Neuroscience | 247.9 |  | 96.1 |  | 344.0 |  |  | 191.9 |  | 147.6 |  | 339.5 |
Other | 82.7 |  | 118.9 |  | 201.5 |  |  | 52.2 |  | 155.4 |  | 207.6 |
Revenue | $ | 10,814.2 |  | $ | 4,743.4 |  | $ | 15,557.7 |  |  | $ | 7,835.2 |  | $ | 3,467.5 |  | $ | 11,302.8 |
(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the six months ended June 30, 2025 and 2024:
| Six Months Ended June 30,
| 2025 |  | 2024
| U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total
Cardiometabolic Health: |  |  |  |  |  |  |
Mounjaro | $ | 5,957.7 |  | $ | 3,083.0 |  | $ | 9,040.7 |  |  | $ | 3,934.0 |  | $ | 963.4 |  | $ | 4,897.4 |
Zepbound | 5,685.4 |  | 7.9 |  | 5,693.3 |  |  | 1,760.6 |  | — |  | 1,760.6 |
Trulicity | 1,514.4 |  | 673.1 |  | 2,187.4 |  |  | 1,958.6 |  | 743.3 |  | 2,701.9 |
Jardiance(1) | 692.0 |  | 1,012.4 |  | 1,704.3 |  |  | 797.1 |  | 659.0 |  | 1,456.1 |
Other cardiometabolic health | 1,090.6 |  | 834.5 |  | 1,925.3 |  |  | 1,355.8 |  | 835.9 |  | 2,191.6 |
Total cardiometabolic health | 14,940.1 |  | 5,610.9 |  | 20,551.0 |  |  | 9,806.1 |  | 3,201.6 |  | 13,007.6 |
Oncology: |  |  |  |  |  |  |
Verzenio | 1,586.6 |  | 1,061.5 |  | 2,648.2 |  |  | 1,499.6 |  | 882.6 |  | 2,382.2 |
Other oncology | 878.5 |  | 834.5 |  | 1,712.9 |  |  | 773.9 |  | 812.5 |  | 1,586.5 |
Total oncology | 2,465.1 |  | 1,896.0 |  | 4,361.1 |  |  | 2,273.5 |  | 1,695.1 |  | 3,968.7 |
Immunology: |  |  |  |  |  |  |
Taltz | 1,025.3 |  | 584.2 |  | 1,609.5 |  |  | 886.4 |  | 542.3 |  | 1,428.8 |
Other immunology | 253.7 |  | 480.4 |  | 734.1 |  |  | 110.5 |  | 377.1 |  | 487.5 |
Total immunology | 1,279.0 |  | 1,064.6 |  | 2,343.6 |  |  | 996.9 |  | 919.4 |  | 1,916.3 |
Neuroscience | 437.2 |  | 178.9 |  | 616.1 |  |  | 355.1 |  | 373.5 |  | 728.6 |
Other | 182.2 |  | 232.2 |  | 414.4 |  |  | 98.0 |  | 351.6 |  | 449.6 |
Revenue | $ | 19,303.7 |  | $ | 8,982.5 |  | $ | 28,286.2 |  |  | $ | 13,529.6 |  | $ | 6,541.2 |  | $ | 20,070.8 |
(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. The following table summarizes revenue by geographical area:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Revenue(1): |  |  |  |  |  |  |
U.S. | $ | 10,814.2 |  |  | $ | 7,835.2 |  |  | $ | 19,303.7 |  |  | $ | 13,529.6 |
Europe | 2,574.4 |  |  | 1,403.7 |  |  | 4,963.1 |  |  | 2,844.4 |
Japan | 521.0 |  |  | 462.7 |  |  | 923.2 |  |  | 826.6 |
China | 465.9 |  |  | 395.1 |  |  | 916.7 |  |  | 771.3 |
Rest of world | 1,182.1 |  |  | 1,206.1 |  |  | 2,179.5 |  |  | 2,098.9 |
Revenue | $ | 15,557.7 |  |  | $ | 11,302.8 |  |  | $ | 28,286.2 |  |  | $ | 20,070.8 |
(1) Revenue is attributed to the countries based on the location of the customer or other party.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration